German drug manufacturing company Boehringer Ingelheim GmbH has agreed to settle approximately 4,000 lawsuits for $650 million. The lawsuits were filed over blood thinning drug Pradaxa, which has been linked to more than 540 patient deaths.
Boehringer is seeking to settle these lawsuits before the first U.S. trial on the matter begins in September. The settlement would provide an average per-case payout of approximately $162,500.
In Illinois, 2,500 lawsuits have been consolidated while another 1,500 are in state courts throughout Connecticut, California and Delaware.
According to Bloomberg, patients and their families are alleging that the drug manufacturers executives knew that Pradaxa was deadly when it was introduced to the market back in October 2010. Just one week ago, Boehringer announced that they had re-analyzed a company-funded study that had been used to win approval for Pradaxa. The new analysis revealed that more than 20 serious hemorrhaging adverse events had not been included in the original report.
Additionally, last year researchers came up with an experimental antidote for Pradaxa which has now generated more than $1 billion in sales for Boehringer. Documents that were made public as part of patients lawsuits revealed that officials did not disclose a data analysis that indicated Pradaxa may have caused more fatal bleeding cases after it was cleared for sale than the when it was initially studied.
As of 2011, the FDA had received more than 540 claims that the drug has caused the death of a patient and an additional 3,780 reports of serious medical complications.
Have you or a loved one suffered side-effects linked to Pradaxa? Have you lost a loved one due to this dangerous drug? The Pradaxa lawyers at Gordon & Doner are ready to help you fight for your rights.